Generic versions of lenacapavir, a twice-yearly injectable HIV-prevention drug, will be available in 120 low- and middle-income countries for $40 annually beginning in 2027. Unitaid and the Gates Foundation have partnered with Indian pharmaceutical companies to produce these affordable generic versions, which have shown to reduce the risk of HIV transmission by over 99.9 percent. This initiative expands access to the drug, currently priced at $28,000 per year in the United States, marking a significant step in global HIV prevention efforts. This will help with the efforts to end the HIV epidemic.
Read More
The FDA has approved lenacapavir, marketed as Yeztugo, a groundbreaking twice-yearly injection offering nearly complete protection against HIV. This capsid inhibitor, recognized as a major scientific breakthrough, has the potential to end the 44-year-long epidemic. To ensure global access, the manufacturer has entered royalty-free licensing agreements with generic drug producers and will supply the drug at no profit to countries in need, in partnership with the Global Fund. This preventative medication aims to transform HIV prevention by addressing adherence and stigma challenges associated with previous PrEP regimens.
Read More
The U.S. has approved lenacapavir (Yeztugo), a twice-yearly HIV prevention injection, marking a potential global breakthrough. Highly effective in clinical trials, reducing new infections nearly to zero in some groups, it offers a longer-lasting alternative to daily PrEP pills. However, access remains a concern due to U.S. healthcare funding cuts and global disparities, potentially limiting its impact despite Gilead’s efforts to provide low-cost versions in some countries. The high initial price also poses a challenge to widespread adoption.
Read More
Lenacapavir, a twice-yearly HIV prevention injection, is poised for US launch this week, with regulatory approval expected June 19th. While estimated to cost around $25,000 annually, independent analysis suggests a production cost as low as $25 per year, raising concerns about potential exorbitant pricing. UNAIDS urges Gilead to prioritize affordability, emphasizing the drug’s potential to end the HIV pandemic, while Gilead cites research and development costs and global pricing considerations. Gilead has agreements for low-cost lenacapavir in 120 low-income countries, but significant access gaps remain.
Read More
I find it truly remarkable that a potential breakthrough in HIV prevention is within reach, with a vaccine that could cost as little as $40 a year per patient. The introduction of lenacapavir, an injection that can prevent infection and suppress HIV, is indeed a significant step forward in the fight against this global health crisis. The prospect of having an injection that only needs to be administered every six months and can provide such crucial protection is a game-changer. It is something that could potentially revolutionize the way we approach HIV prevention.
However, the reality of the situation quickly becomes grim when we realize that the actual cost of taking this vaccine in the USA is staggering.… Continue reading
John Q. Hosedrinker